Navigation Links
Verus Pharmaceuticals Announces a Lawsuit Against AstraZeneca AB and Tika Lakemedel AB
Date:5/27/2009

SAN DIEGO, May 27 /PRNewswire/ -- Verus Pharmaceuticals, Inc. ("Verus"), a specialty pharmaceutical company, announced today that it has filed a lawsuit against AstraZeneca AB ("AstraZeneca") and Tika Lakemedel AB ("Tika") in the Supreme Court of the State of New York, in which it is seeking $1.3 billion on claims of fraud, breach of contract, and conversion. Verus claims that AstraZeneca and its wholly owned subsidiary Tika disregarded their obligations under three agreements with Verus, entered into in 2007, pursuant to which the defendants were to pursue the research and development of Verus' assets, including budesonide, a steroid for the treatment of pediatric asthma in the United States. Verus further alleges that defendants' representations that induced Verus to enter into the agreements constituted fraud.

About Verus

Verus is dedicated to improving the lives of children and those who care for them. More information about Verus is available on the company's corporate website at www.veruspharm.com.

Verus(R) is a registered trademark of Verus Pharmaceuticals, Inc.

Forward-Looking Statements

Verus cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Verus that any of its plans will be achieved. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in Verus' business. All forward-looking statements are qualified in their entirety by this cautionary statement and Verus undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

    Company Contact:
    Blair C. Fensterstock, Esq.,
    Managing Director
    Fensterstock & Partners LLP
    BFensterstock@fensterstock.com
    212-785-4100 Office; 917-689-1137 Cell


'/>"/>
SOURCE Verus Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Adolescent Growth Plate Injuries May Be Related to Overuse
2. AUDIO from Medialink and Ortho-McNeil-Janssen Pharmaceuticals: Risks of Overusing Antibiotics
3. Kids Overuse Sports Injuries Are on the Rise
4. Study Asks: Are Physicians Overusing an Invasive Cardiac Treatment?
5. Urgent need for research into the best treatment for medication overuse headaches
6. Verus Pharmaceuticals Announces Divestiture of Pediatric GI Development Program to Meritage Pharma
7. Overuse of Opioids, Barbiturates Boosts Chronic Migraine Risk
8. ReachMD and VerusMed Broadcast Medical Conference Coverage on XM Satellite Radio
9. Verus Pharmaceuticals Announces Promotion of Robert W. Keith to Chief Executive Officer
10. Verus Pharmaceuticals Announces Divestiture of Pediatric Asthma Development Programs to AstraZeneca
11. Access Pharmaceuticals Provides Update on Global Launch of MuGard(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2017)... MD (PRWEB) , ... July 27, 2017 , ... ... Teams of entrepreneurs will compete to form startup companies around 117 breakthrough inventions ... Heart, Lung, and Blood Institute, and National Institute of Biomedical Imaging and Bioengineering), ...
(Date:7/27/2017)... ... July 27, 2017 , ... Cremations recently surpassed traditional burials ... Association, this trend is expected to continue with over 70% of Americans projected to ... demand for new innovations that enable families to celebrate the life of a lost ...
(Date:7/26/2017)... ... 2017 , ... An inventor from Salisbury, N.C., knows the difficulties involved with ... and dignified way to keep leeches in place during therapy," she said. "That’s why ... an effective way to keep a leech in place on the skin during therapy. ...
(Date:7/26/2017)... ... July 26, 2017 , ... Written By: ... a major advancement in drug therapy for patients living with relapsing and primary ... a novel B cell targeted therapy that has been proven to significantly reduce ...
(Date:7/26/2017)... , ... July 26, 2017 , ... ... Management Solutions as part of their continued efforts to provide innovative offerings to ... the best IT resources and build dynamic, high-performing teams to address healthcare IT’s ...
Breaking Medicine News(10 mins):
(Date:7/20/2017)... -- Prime Therapeutics LLC (Prime) released this statement from its Chief ... for Clinical and Economic Review,s (ICER) public meeting ... of abuse-deterrent formulations (ADF) of opioids. Prime was the sole ... "The ICER data ... use of abuse-deterrent formulations (ADF) in opioids in terms of ...
(Date:7/14/2017)... 14, 2017 Endo International plc (NASDAQ: ENDP ... 8, 2017.  Members of its senior management team will host a ... 8:30 a.m. ET. The dial-in number to access ... (678) 509-7598, and the passcode is 45397076. Please dial in 10 ... A replay of the call will be available ...
(Date:7/13/2017)...  New York City-based market research firm Kalorama Information notes ... of.  From new products to new costs, to the threat ... completed study, Potential Pipeline Disruptors . Among ... 1.  Age-Driven Growth - True Impact Moment Arriving   ... impact the growing population and, to a more extreme extent, ...
Breaking Medicine Technology: